Press Release from Merck & Co. Inc. Published: 03 June 10, Merck announced today the results of a noninferiority trial of a new antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV), the dose of 150 mg in combination with 5-HT3 antagonist and dexamethasone, compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy …
Pictures of Eczema – Infant Children Adult